Nebenwirkungen · Imfinzi
IMFINZI 50 mg/ml concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 29
HOS-141867 · Präparat HOS-098696
In patients treated with IMFINZI in combination with tremelimumab and platinum-based chemotherapy, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 6.2% for alanine aminotransferase increased, 5.2% for aspartate aminotransferase increased, 4.0% for blood creatinine increased, 9.4% for amylase increased and 13.6% for lipase increased. The proportion of patients who experienced a TSH shift from baseline that was ≤ ULN to > ULN was 24.8% and a TSH shift from baseline that was ≥ LLN to < LLN was 32.9%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-18T16:10:00Z · SHA-256 2aea150cfee5fbe605596424a5c30efdb4cdb269005b61f75a72ebb78beb905f · Passage 543a3854cdd22c7474e70d59bc005d96761babdaded0a94750020bb4f85c4e33 · Zeichen 55719–56295 im Abschnitt